is tirzepatide being discontinued A Major GLP-1 Drug Shortage Over. Some Patients Aren't Celebrating FDA sets tirzepatide compounding deadlines

Clinical studies demonstrate substantial HbA1c reductions (up to ?2.4%) and body weight losses exceeding 20% with high-dose regimens in people with obesity and type 2 diabetes 1,2

That meant drug compounderspharmacists, facilities, and others who mix ingredients to create medications in shortagesmust stop producing copies of semaglutide, the active ingredient in Novos drug

These agents mimic GLP-1, an endogenous incretin hormone released in response to eating

Clinical trails show that Mounjaro leads to an average weight loss of nearly 25% after one year, compared to Wegovy's average weight loss of around 16%

But research suggests that up to 120g can be eaten daily, without weight gain (9)

Next, we determined if the BHZ signal noted in the gain-of-function experiment colocalizes with type I and type IV collagens, which are the major extracellular protein substrates of LOXs, by co-immunofluorescence staining